Puli Pharmaceuticals' new modified drug, left ethyl iracetam, is on the market.

Left beta-laxitan is an anti-epileptic drug that is a derivative of pyridoxine.
its anti-epileptic mechanism mainly regulates the release of neurotransmitter by binding to the synth follicle protein SV2A in the brain, participating in the polymerization and cell spitting of the follicles.
the drug was first developed by UCB PHARMACEUTICALS INC and went on sale in the United States in 1999.
, the drug has four dosage forms on the domestic market, including ordinary tablets, slow-release tablets, oral liquids, injections, of which tablets and oral liquids for Health Insurance B.
2018, the global market sales of Zo-Iracetam preparation products were approximately US$2,114 million, and the sales of tablets in grade hospitals nationwide were approximately RMB894 million.
, the variety has been partially dosage forms collected.
according to the Insight database, the left ethyl laxitan tablet belongs to the 4 plus 7 collection varieties, and the oral liquid and injection thick solution belong to the third batch of national harvesting varieties.
.